Development

Opus enters a strategic collaboration with Resilience for AAV-based gene therapy development and manufacturing for inherited retinal diseases.

IAVI and Moderna have announced a new collaboration to employ mRNA technology to meet the challenge of a range of global health issues.

Evonetix’s thermally controlled DNA synthesis technology is designed to enable highly parallel DNA synthesis in a benchtop platform.

NIH has announced four new grant awards to fund new tuberculosis research advancement centers.

Sterling Pharma Solutions has unveiled a £1 million expansion project to increase its capabilities and laboratories capacity at its Deeside, UK site.

The recent success of mRNA vaccines has opened the door for further and future development of nucleic acid-based therapies.

The growing demand for antibody and other bio-therapeutics will require long-term scale-up solutions.

Under the two-year task order, ATCC will continue to support the DCEG MEAS program in receiving, processing, storing, analyzing, and distributing clinical specimens from different cancer types.

3D cell cultures could provide key avenues to unlocking critical information.

Advances in pharmaceutical neuroscience present an opportunity for pharmaceutical companies to stay ahead of the curve.

Sanofi and IGM Biosciences have announced a collaboration agreement for oncology, immunology, and inflammation targets.

Orion is planning to refocus its R&D efforts on the development of new proprietary products focused on cancer and pain.

Huma has acquired AstraZeneca’s digital health platform, and AstraZeneca has become a shareholder of Huma in a partnership to accelerate digital-first patient care.

Gamma Biosciences has announced an initiative through its subsidiary, Mirus Bio, to develop lipid-polymer nanocomplexes for improve mRNA delivery solutions.

Sanofi is collaborating with Blackstone Life Sciences to accelerate the development of a treatment for multiple myeloma.

Sanofi and Seagen have entered an agreement to investigate three cancer targets.

Catalent has announced the completion of a $30 million project at its facility in Limoges, France focused on biopharmaceutical development and drug product manufacturing.

NIH has launched one of the first Phase 1 clinical trials to examine mRNA technology for HIV.

CAR-T cell therapy development is a complex process that requires standardization.

SCG Cell Therapy has signed a collaboration agreement with A*STAR’s BTI to advance the development of antibodies for infectious diseases and cancer treatments.

Novo Nordisk will expand its existing research collaboration in novel delivery technologies with MIT and Brigham and Women’s Hospital.

New technologies are treatments are emerging to tackle COVID-19 and its assortment of new variants.

A rise in investments and funding into regenerative medicines projects has helped to advance a rich clinical pipeline.

Researchers at McGill University have made advancements with a novel method for growing synthetic bone tissue.

FDA’s CDER continues to make rare diseases a priority with drug approvals and programming to speed therapeutic development.